Company Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process.
Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin’s lymphomas, including mantle cell lymphoma and double hit lymphoma.
The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation.
In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment.
Further, the company’s artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data.
Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications.
The company was incorporated in 2013 and is headquartered in Dallas, Texas.
| Country | United States |
| Founded | 2013 |
| IPO Date | Jun 11, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Panna Sharma |
Contact Details
Address: 1920 McKinney Avenue, 7th Floor Dallas, Texas 75201 United States | |
| Phone | 972 277 1136 |
| Website | lanternpharma.com |
Stock Details
| Ticker Symbol | LTRN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001763950 |
| CUSIP Number | 51654W101 |
| ISIN Number | US51654W1018 |
| Employer ID | 46-3973463 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Panna Sharma | President, Chief Executive Officer and Director |
| David R. Margrave | Chief Financial Officer and Secretary |
| Dr. Kishor Gopaldas Bhatia Ph.D. | Chief Scientific Officer and Scientific Consultant |
| Nicole Leber | Investor Relations Associate, Finance and Administrative Coordinator |
| Dr. Peter L. Nara D.V.M., M.S., Ph.D. | Co-Founder and Advisor |
| Ernest Kitt B.S., M.S | Head of Clinical Operations |
| Dr. Marc C. Chamberlain M.D. | Chief Medical Officer of Starlight Therapeutics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 8, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Jun 17, 2024 | 8-K | Current Report |
| Jun 10, 2024 | EFFECT | Notice of Effectiveness |
| Jun 3, 2024 | UPLOAD | Filing |
| May 24, 2024 | 8-K | Current Report |
| May 24, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |